The DOCK11 Knockout HAP1 Polyclonal Cells represent a rigorously validated CRISPR/Cas9-edited polyclonal knockout cell population targeting the human DOCK11 gene in the HAP1 host cell background. This gene-disrupted model is designed for researchers investigating DOCK11-dependent signaling mechanisms, cytoskeletal regulation, and immune cell function. The polyclonal format provides a heterogeneous pool of edited cells, enabling robust loss-of-function studies without the clonal selection biases inherent in monoclonal lines. By disrupting the endogenous DOCK11 locus, these cells offer a versatile platform for dissecting the molecular pathways orchestrated by this guanine nucleotide exchange factor in a near-haploid genetic environment.
The HAP1 cell line is an adherent, near-haploid cell model originally derived from the KBM-7 chronic myeloid leukemia cell line. Its haploid nature simplifies genetic manipulation and reduces the complexity of interpreting knockout phenotypes, making HAP1 an ideal host for functional genomics and signaling studies. While HAP1 cells retain certain leukemic characteristics, they express a broad repertoire of signaling components relevant to hematopoietic lineages, rendering them particularly suitable for investigating genes such as DOCK11 that regulate actin dynamics and cell migration. The cells grow in standard culture conditions, supporting reproducible and scalable experimental workflows.
DOCK11 functions primarily as a guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP on the small GTPase CDC42, thereby switching it into an active conformation. This activation is triggered by upstream signals from chemokine receptors, such as CCR7 responding to CCL19/CCL21, or CXCR4 binding CXCL12, and is mediated through an ELMO-dependent mechanism. Once activated, DOCK11 forms a complex with ELMO1 and ELMO2 to promote localized CDC42?CGTP accumulation. Active CDC42 then engages downstream effectors including PAK kinases and the WASP/WAVE complex, which in turn stimulate the ARP2/3 complex to nucleate actin polymerization. This cascade drives cell polarization, lamellipodia formation, and directed migration, central to lymphocyte trafficking and immune synapse assembly.
In the HAP1 host context, targeted disruption of DOCK11 creates a powerful system to elucidate its roles in both normal immune cell biology and pathophysiological processes. Because DOCK11 is implicated in actin-dependent processes such as chemotaxis and adhesion, the knockout cells can be employed to model aspects of combined immunodeficiency 23, an early-onset autoimmune disorder linked to DOCK11 mutations. Furthermore, the dysregulation of CDC42 signaling and actin remodeling is a hallmark of metastatic cancer cells, making this model relevant for oncology studies. The simplified haploid background minimizes genetic redundancy, allowing clearer attribution of phenotypic changes to DOCK11 loss and facilitating high-content screening approaches.
These DOCK11 knockout cells are suitable for a wide array of experimental applications, including transwell chemotaxis assays to measure directed cell migration, phalloidin staining to visualize F-actin organization, and CDC42 activation pull-down assays to quantify GTP-bound CDC42 levels. Western blotting for DOCK11 and phosphorylated PAK provides direct readouts of pathway activity, while flow cytometry and immunofluorescence enable detailed analysis of cell surface receptor expression and polarity markers. Applications extend to functional genomics screens, drug target validation, and mechanistic dissection of chemokine and T cell receptor signaling pathways. For additional information or technical support, please contact Ascent Research.
